Literature DB >> 21867695

Effects of a single dose of oral iron on hepcidin concentrations in human urine and serum analyzed by a robust LC-MS/MS method.

Sun-Il Hwang1, Yong-Yook Lee, Jung-Ok Park, H James Norton, Elene Clemens, Laura W Schrum, Herbert L Bonkovsky.   

Abstract

BACKGROUND: The measurement of serum hepcidin, a peptide hormone that regulates iron metabolism, is clinically important to the understanding of iron homeostasis in health and disease. To date, the quantification of serum hepcidin levels by conventional immunological detection methods has proven problematic due to challenges in obtaining high quality antibodies which demonstrate good reproducibility. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) has been employed recently for more sensitive quantification of hepcidin; however, this method has high background levels and therefore less than optimal specificity.
METHODS: In order to increase the specificity of the mass spectrometry based assay, we developed a robust, ultra-performance liquid-chromatography-tandem mass spectrometry (UPLC-MS/MS) protocol using multiple selected reaction monitoring (mSRM) for quantification of hepcidin levels in urine and serum of human subjects. With this assay, we assessed levels of hepcidin before and for up to 8 h after oral ingestion of ferrous sulfate in ten adult human subjects without known disease.
RESULTS: The linear response of hepcidin quantitation on each instrument was measured, and the correlation coefficients of these calibrations were r(2)=0.9512±0.0202 (n=5) for urine and r(2)=0.9709±0.0291 (n=5) for serum [r(2)=mean±SD]. Compared to baseline, the levels of urinary hepcidin between 2-4 h and 4-8 h of both women and men showed significant increases with p<0.05 and p<0.001, respectively. The levels of serum hepcidin between 4 h and 8 h in both women and men showed significant increases, compared with baseline values, with both p<0.01. Interestingly, we also observed some degree of oscillation of levels, occurring at later time points.
CONCLUSIONS: We have developed and validated a new method for measuring hepcidin concentrations in human serum and urine and used it to demonstrate early increases with iron supplement in both urinary and serum levels of hepcidin, which return to baseline levels, except in urine samples from men.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21867695      PMCID: PMC3207492          DOI: 10.1016/j.cca.2011.08.014

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  36 in total

1.  Quantification of hepcidin-25 in human serum by isotope dilution micro-HPLC-tandem mass spectrometry.

Authors:  Uwe Kobold; Thomas Dülffer; Markus Dangl; Achim Escherich; Manfred Kubbies; Ralf Röddiger; Jo Anne Wright
Journal:  Clin Chem       Date:  2008-09       Impact factor: 8.327

Review 2.  Hepcidin and iron metabolism: from laboratory to clinical implications.

Authors:  Massimo Franchini; Martina Montagnana; Giuseppe Lippi
Journal:  Clin Chim Acta       Date:  2010-07-08       Impact factor: 3.786

3.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

Review 4.  Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.

Authors:  H L Bonkovsky; J V Obando
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

5.  The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation.

Authors:  Gaël Nicolas; Caroline Chauvet; Lydie Viatte; Jean Louis Danan; Xavier Bigard; Isabelle Devaux; Carole Beaumont; Axel Kahn; Sophie Vaulont
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 6.  Iron in nonhemochromatotic liver disorders.

Authors:  Vamsee Alla; Herbert L Bonkovsky
Journal:  Semin Liver Dis       Date:  2005-11       Impact factor: 6.115

7.  Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone.

Authors:  Bomee Chung; Frédérique Verdier; Pavle Matak; Jean-Christophe Deschemin; Patrick Mayeux; Sophie Vaulont
Journal:  FASEB J       Date:  2010-02-02       Impact factor: 5.191

8.  Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia.

Authors:  H Kulaksiz; S G Gehrke; A Janetzko; D Rost; T Bruckner; B Kallinowski; W Stremmel
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 9.  Iron homeostasis: fitting the puzzle pieces together.

Authors:  Tomas Ganz
Journal:  Cell Metab       Date:  2008-04       Impact factor: 27.287

10.  High-throughput matrix-assisted laser desorption ionization-time-of-flight mass spectrometry method for quantification of hepcidin in human urine.

Authors:  Damon S Anderson; Matthew M Heeney; Udo Roth; Christoph Menzel; Mark D Fleming; Hanno Steen
Journal:  Anal Chem       Date:  2010-02-15       Impact factor: 6.986

View more
  3 in total

1.  Catechins in dietary supplements and hepatotoxicity.

Authors:  Victor J Navarro; Herbert L Bonkovsky; Sun-Il Hwang; Maricruz Vega; Huiman Barnhart; Jose Serrano
Journal:  Dig Dis Sci       Date:  2013-04-27       Impact factor: 3.199

2.  Effect of Intravenous Iron Supplementation on Hepcidin Levels in Iron Deficient Pregnant Females in Second and Third Trimester.

Authors:  Amtuz Zehra; Saleh Mohammed Saleh Abdullah; Muhammad Saboor
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-31       Impact factor: 0.900

3.  A Targeted Mass Spectrometric Assay for Reliable Sensitive Hepcidin Quantification.

Authors:  Ahmed Moghieb; Lia Tesfay; Song Nie; Marina Gritsenko; Thomas L Fillmore; Jon M Jacobs; Richard D Smith; Frank M Torti; Suzy V Torti; Tujin Shi; Charles Ansong
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.